TechonoDerma is an innovation-oriented R&D biotech focusing on the development of novel small molecule drugs for dermatological conditions. Located in Jiaxing Xiuzhou Biopharmaceutical National Park, TechnoDerma has been designated as a leading enterprise by the Jiaxing Municipal Government of Zhejiang Province.
The company's current R&D pipeline includes candidate drugs for androgenetic alopecia (AGA), atopic dermatitis (AD), psoriasis, and systemic lupus erythematosus (SLE). TechnoDerma's first and the most advanced research and development program is the first-in-class small molecule drug candidate TDM-105795 for the treatment of AGA, which will finish Phase I clinical trial by end of 2022 and begin Phase II trial in early 2023. The IND application for the second program, which involves a topical drug, TDM-180935, for the treatment of AD, has been approved by FDA on Aug 1st, 2022. Several ongoing programs aim at submitting IND applications for the treatment of psoriasis and SLE in Q3-Q4 2023 and 2024, respectively. In addition, TechnoDerma has been conducting innovative research to identify novel targets and small molecules for other skin conditions such as hyper scarring, thereby further strengthening the company’s R&D capacity.